Impact of Race on Progression-Free Survival and Overall Survival in Patients with Multiple Myeloma

被引：0
|
作者：
Wani, Kashmira [1 ]
Gutta, Radhika [2 ]
Mittal, Aayush [1 ]
Jamil, Maria [1 ]
Springer, Kylie [1 ]
Kuriakose, Philip [2 ]
机构：
[1] Henry Ford Hlth, Detroit, MI USA
[2] Henry Ford Hlth, Hematol & Oncol, Detroit, MI USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-191157
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Immunoglobulin Recovery after ASCT for Patients with Multiple Myeloma: Impact on Overall Survival and Progression-Free Survival
    Jimenez-Zepeda, Victor
    Duggan, Peter
    Neri, Paola
    Chaudhry, Ahsan
    Tay, Jason
    Bahlis, Nizar J.
    [J]. BLOOD, 2016, 128 (22)
  • [2] Impact of interferon maintenance therapy on multiple myeloma patients' quality of life, progression-free survival and overall survival
    Bumeder, I
    Tyroller, M.
    Fischer, N.
    Busch, R.
    Frick, E.
    [J]. PSYCHO-ONCOLOGY, 2006, 15 (02) : S187 - S188
  • [3] Soluble MICA as a prognostic factor for the overall survival and progression-free survival of multiple myeloma patients
    Rebmann, V.
    Schuett, P.
    Brandhorst, D.
    Opalka, B.
    Nowrousian, M. R.
    Moritz, T.
    Grosse-Wilde, H.
    [J]. TISSUE ANTIGENS, 2007, 69 (05): : 390 - 390
  • [4] Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma
    Dimopoulos M.
    Sonneveld P.
    Manier S.
    Lam A.
    Roccia T.
    Schecter J.M.
    Cost P.
    Pacaud L.
    Poirier A.
    Tremblay G.
    Lan T.
    Valluri S.
    Kumar S.
    [J]. BMC Cancer, 24 (1)
  • [5] PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    Dimopoulos, M.
    Sonneveld, P.
    Nahi, H.
    Kumar, S.
    Hashim, M.
    Kulakova, M.
    Duran, M.
    Heeg, B.
    Lam, A.
    Dearden, L.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A408 - A408
  • [6] Association of Morbid Progression With Overall Survival Among Patients With Multiple Myeloma: Validation of the Progression-free Survival Endpoint
    Rosenberg, Aaron S.
    Facon, Thierry
    Parikh, Kejal
    Chung, Weiyuan
    Srinivasan, Shankar
    Kotey, Stanley
    Tuscano, Joseph
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (05): : 345 - +
  • [7] Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients
    Rebmann, Vera
    Schuett, Philipp
    Brandhorst, Dieter
    Opalka, Bertram
    Moritz, Thomas
    Nowrousian, Mohammad Reza
    Grosse-Wilde, Hans
    [J]. CLINICAL IMMUNOLOGY, 2007, 123 (01) : 114 - 120
  • [8] Morbid Progression Is Common Among Patients with Multiple Myeloma and Is Associated with Shortened Overall Survival: Validation of the Progression-Free Survival Endpoint
    Rosenberg, Aaron Seth
    Facon, Thierry
    Abouzaid, Safiya
    Srinivasan, Shankar
    Chung, Weiyuan
    Parikh, Kejal
    Tuscano, Joseph
    [J]. BLOOD, 2017, 130
  • [9] Impact of Etiological Cytogenetic Abnormalities on Immunoparesis and Progression-Free and Overall Survival in Newly Diagnosed Multiple Myeloma
    Caro, Jessica
    Cairns, David
    Menzies, Tom
    Pawlyn, Charlotte
    Boyle, Eileen M.
    Morgan, Gareth
    Cook, Gordon
    Kaiser, Martin F.
    Owen, Roger G.
    Gregory, Walter M.
    Jackson, Graham H.
    Walker, Brian
    Heaney, Jennifer Lj
    Drayson, Mark T.
    Davies, Faith E.
    [J]. BLOOD, 2020, 136
  • [10] Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma
    Dimopoulos, M. A.
    Hussein, M.
    Swern, A. S.
    Weber, D.
    [J]. LEUKEMIA, 2011, 25 (10) : 1620 - 1626
12345